INTRODUCTION
============

The annual prevalence of Bell's palsy in the general population has been reported to range from 11.5 to 40.2 per 100,000 persons \[[@b1-ceo-2018-01018]\]. Viral inflammation and immune mechanisms are thought to play a major role in the pathogenesis of Bell's palsy \[[@b2-ceo-2018-01018]\], in as much as herpes simplex virus-1 has been detected in the endoneurial fluid of facial nerves in Bell's palsy patients \[[@b3-ceo-2018-01018]\], and recent studies have suggested that the neutrophil to lymphocyte ratio (NLR) is higher in patients with than without Bell's palsy \[[@b4-ceo-2018-01018]-[@b6-ceo-2018-01018]\]. NLR is regarded as a marker of inflammation, as well as being used to assess the risk of cardiovascular disease and the prognosis of patients with cardiovascular disease and with several types of cancer \[[@b7-ceo-2018-01018]-[@b10-ceo-2018-01018]\].

Electroneuronography (ENoG) was the first tool used to predict the prognosis of patients with Bell's palsy in the early 1970s \[[@b11-ceo-2018-01018]\]. Other prognostic methods include electromyography (EMG), nerve excitability test, maximal stimulation test, blink reflex test, and vestibular evoked myogenic potential. However, ENoG and EMG, the primary methods used in clinical practice, have several disadvantages. Guidelines recommend that ENoG and EMG be performed after 3 and 14 days of facial paralysis, respectively \[[@b12-ceo-2018-01018]\]. In addition, no currently known method can predict recovery time in patients with Bell's palsy \[[@b13-ceo-2018-01018]\]. This study therefore evaluated the associations between NLR and the severity of and recovery time from Bell's palsy.

MATERIALS AND METHODS
=====================

Study population
----------------

This retrospective study included patients in Kyung Hee Medical Center who were diagnosed with Bell's palsy from 2015 to 2017. All patients underwent physical examination by an ENT specialist, with the severity of Bell's palsy assessed by House-Brackmann (H-B) grade. Body mass index (BMI) was calculated from each patient's height and weight. Complete blood count, differential count, and glycated hemoglobin (HbA1c) concentration were also measured. Patients with traumatic facial palsy, facial palsy of central origin, recurrent facial palsy, Ramsay-Hunt syndrome, or a previous history of otologic surgery were excluded, as were patients who first presented ≥5 days after facial paralysis first occurred, and patients with hematologic disease. Patient information was anonymized, and the study protocol was approved by the Institutional Review Board of Kyung Hee Medical Center (IRB No. 2017-01-009). As this was a retrospective study, no informed consent was required.

Treatment process
-----------------

All patients were treated with steroids and the antiviral agent famciclovir. The steroid treatment schedule consisted of 80 mg/day for 4 days, 60 mg/day for 2 days, 40 mg/day for 2 days, 20 mg/day for 2 days, and 10 mg/day for 2 days. Patients were also treated with 750 mg/day famciclovir for 7 days. Patients were hospitalized for about 7 days and subsequently visited the outpatient clinic 1 week and 1, 3, and 6 months after discharge. All patients underwent ENoG 5 days after facial paralysis first occurred. The severity of facial paralysis, as determined by H-B grade, was assessed by the same otolaryngologist at every outpatient visit, with H-B grades ≤2 defined as favorable outcomes.

Blood tests
-----------

Blood samples were obtained on the day of admission, within 5 days after the onset of facial paralysis. Platelet, lymphocyte, and neutrophil counts were measured, with the platelet to lymphocyte ratio defined as the platelet count divided by the absolute lymphocyte count, and the NLR as the absolute neutrophil count divided by the absolute lymphocyte count. The upper limit of NLR for healthy adults was set to 3.53 based on previous findings \[[@b14-ceo-2018-01018]\].

Obesity
-------

The World Health Organization standards for Asia-Pacific subjects define persons with BMI \<18.5 kg/m^2^ as underweight, ≥18.5 kg/m^2^ and \<23 kg/m^2^ as normal weight, ≥23 kg/m^2^ and \<25 kg/m^2^ as overweight, ≥25 kg/m^2^ and \<30 kg/m^2^ as obese, and ≥30 kg/m^2^ as severely obese, respectively \[[@b15-ceo-2018-01018]\]. In this study, obesity was defined as a BMI ≥25 kg/m^2^ and normal weight as a BMI \<25 kg/m^2^.

Severity of initial facial paralysis
------------------------------------

H-B grade 2 was defined as mild facial paralysis, H-B grades 3 and 4 as moderate facial paralysis, and H-B grades 5 and 6 as severe facial paralysis \[[@b16-ceo-2018-01018]\]. Patients were classified into two groups, those with mild to moderate facial paralysis (H-B grades 2--4) and severe facial paralysis (H-B grade 5 or 6).

Recovery time
-------------

Recovery time was defined as the duration from the day facial paralysis first occurred until the day that facial paralysis had improved to H-B grade ≤2.

Statistical analysis
--------------------

All statistical analyses were performed using IBM SPSS ver. 20.0 (IBM Corp., Armonk, NY, USA), with *P*\<0.05 defined as statistically significant. Data are expressed as mean±standard deviation or as frequency and percentage. Normality was assessed using the Shapiro-Wilk W-test. Categorical variables were compared using the chi-square test, and continuous variables were compared using Student *t*-test, Mann-Whitney *U*-test, as appropriate. All calculations included determination of 95% confidence intervals to estimate the effect size and mean differences.

RESULTS
=======

This study included a total of 51 patients, 16 males and 35 females, of age 39.7±20.1 years. Their mean severity of initial facial paralysis was H-B grade 3.8±0.9, and their mean BMI was 23.2±4.2 kg/m^2^, with 16 patients being obese and 35 of normal weight ([Table 1](#t1-ceo-2018-01018){ref-type="table"}).

Classification of these 51 patients by severity of initial facial paralysis showed that 39 (76.5%) had mild to moderate palsy (H-B grades 2--4) and 12 (23.5%) had severe palsy (H-B grades 5--6). These two groups differed significantly in mean recovery time (39.1±28.9 days vs. 78.6±41.3 days, *P*=0.002), mean lymphocyte percentage (27.8%±11.1% vs. 20.5%±9.6%, *P*=0.048), mean NLR (3.5±3.8 vs. 4.8±3.2, *P*=0.048), mean white blood cell (WBC) count (7,912.6±2,627.5/mL vs. 10,415.3±3,503.4/mL, *P*=0.021), mean ENoG score (56.1%±18.8% vs. 33.6%±23.3%, *P*=0.010), and the percentage of obese patients (23.1% \[9/39\] vs. 41.7% \[5/12\], *P*=0.033). In contrast, there were no between-group differences in mean age (38.6±19.5 years vs. 43.3±22.2 years, *P*=0.571) and mean HbA1c concentration (5.7%±0.7% vs. 5.9%±0.7%, *P*=0.154). The percentages of patients with diabetes mellitus (10.3% \[4/39\] vs. 25% \[3/12\], *P*=0.334) and hypertension (23.1% \[9/39\] vs. 16.7% \[2/12\], *P*=1.000) also did not differ significantly ([Table 2](#t2-ceo-2018-01018){ref-type="table"}).

In analyzing the significance of factors related to recovery time from facial paralysis, we found that mean recovery times did not differ significantly between patients with and without hypertension (42.9±28.7 days vs. 50.6±37.8 days, *P*=0.963), with and without diabetes mellitus (71.4±40.4 days vs. 45.3±34.3 days, *P*=0.117), and with normal weight and obesity (44.1±36.3 days vs. 59.5±33.8 days, *P*=0.059). However, mean recovery time was significantly longer in patients with high NLR than normal NLR (66.8±11.2 days vs. 40.7±4.8 days, *P*=0.045) ([Fig. 1](#f1-ceo-2018-01018){ref-type="fig"}). In evaluating factors associated with the severity of initial facial paralysis, we found that mean H-B grades did not differ significantly between patients with and without hypertension (4.0±0.6 vs. 3.8±1.0, *P*=0.592), with and without diabetes mellitus (4.4±0.5 vs. 3.8±0.9, *P*=0.068), and with normal and high NLR (3.7± 0.2 vs. 4.1±0.2, *P*=0.098). In contrast, mean H-B grades differed significantly between normal weight and obese patients (3.6±0.9 vs. 4.3±0.7, *P*=0.010) ([Fig. 2](#f2-ceo-2018-01018){ref-type="fig"}).

DISCUSSION
==========

Many studies have evaluated prognostic factors in Bell's palsy patients. Among the factors associated with the prognosis of patients with Bell's palsy are patient age, severity (i.e., initial H-B grade), time from initial symptoms to the start of recovery, time from initial symptoms to the start of corticosteroid treatment, pain, dyslipidemia, diabetes, hypertension and body weight.

ENoG and EMG remain the tools most frequently used to predict prognosis in patients with Bell's palsy, and stapedial reflex tests may also be useful. These methods, however, have some disadvantages. ENoG should be performed after 3 days of facial paralysis; EMG can first assess pathological spontaneous activity 2 weeks after facial paralysis first occurs, and the accuracy of stapedial reflex tests can be reduced by a middle ear lesion on the ipsilateral side of the paralysis, or if the facial nerve lesion is far from the branch of the nerve that involves the stapedius muscle \[[@b17-ceo-2018-01018]\].

Although these methods can predict recovery time in patients with Bell's palsy, they are not very reliable. This study evaluated whether a parameter determined using a simple blood test, the NLR, could predict recovery time. NLR is an indicator of cellmediated immunodeficiencies associated with systemic inflammation, and can therefore be considered a marker of the inflammatory state of a patient.

The pathophysiology of Bell's palsy may include viral infection, ischemic neuropathy, and autoimmune responses \[[@b2-ceo-2018-01018],[@b18-ceo-2018-01018],[@b19-ceo-2018-01018]\], with a viral inflammatory/immune mechanism thought to play a major role in the pathogenesis of Bell's palsy \[[@b2-ceo-2018-01018]\]. Inflammatory changes resulting from viral infection may result in swelling of the facial nerve, compressing the nerve and resulting in facial nerve paralysis. Increased pressure on the nerve prevents vein reflux, with congestion of the blood vessels leading to a vicious cycle of edema, compression, and ischemia of the facial nerve, a cycle considered an important factor related to poor prognosis in patients with facial paralysis \[[@b20-ceo-2018-01018],[@b21-ceo-2018-01018]\].

Immune system cells, including lymphocytes, neutrophils, and monocytes, as well as cell-mediated inflammatory responses, are recognized as important in tumorigenesis and carcinogenesis \[[@b22-ceo-2018-01018]\]. NLR has therefore been evaluated as a prognostic factor in patients with head and neck, pancreatic, and ovarian cancer. Relative to normal NLR, elevated NLR had a hazard ratio (HR) for survival in all patients with head and neck cancer of 1.78, including HRs in patients with cancers of the oral cavity, nasopharynx, larynx, and hypopharynx of 1.56, 1.66, 1.55, and 2.36, respectively \[[@b10-ceo-2018-01018]\]. In patients with ovarian cancer, elevated NLR had an HR of 1.63 \[[@b9-ceo-2018-01018]\]. In addition, the overall survival rate of patients with metastatic pancreatic cancer was significantly lower when NLR was \>3.75 \[[@b8-ceo-2018-01018]\]. Because the development of Bell's palsy has been associated with an inflammatory mechanism, NLR may be predictive of outcomes in patients with this condition, with studies suggesting that NLR is higher in patients with Bell's palsy than in normal subjects \[[@b5-ceo-2018-01018],[@b22-ceo-2018-01018]\]. Furthermore, high NLR was found to be associated with poor prognosis in patients with Bell's palsy \[[@b23-ceo-2018-01018]\]. We found that NLR differed significantly between groups of patients with mild to moderate and severe facial paralysis. Although the severity of initial facial paralysis did not differ significantly between groups of patients with normal and high NLR (*P*=0.098), their mean H-B grades were 3.7±0.2 and 4.1±0.2, respectively. The finding that H-B grade was generally high in patients with high NLR suggested a correlation between the severity of facial paralysis and NLR. In contrast, the upper limit of NLR had not been clearly defined until recently, with various studies differing in the upper limit of NLR. Because a study in 413 healthy adults found that the mean NLR was 1.65 and the upper limit was 3.53 \[[@b14-ceo-2018-01018]\], our study set the upper limit of NLR at 3.53.

We also found that the time to recovery from facial palsy was significantly longer in the high than in the normal NLR group. Similar to other peripheral nerves, the facial nerve was found to have a series of planned changes for recovery following injury. Nerve injury induces inflammation, causing WBCs to aggregate at the site of injury. Cells of the innate immune system aggregate within a few hours to several days after injury. Neutrophils contain toxic substances that interfere with the growth of bacteria and fungi, kill these microorganisms, and reach the infected area the fastest. In animals, neutrophils present at the site of neuronal damage were found to affect pain sensitivity, but not peripheral nerve regeneration \[[@b24-ceo-2018-01018]\], although the effects of neutrophils and lymphocytes on axon regeneration have yet to be clarified \[[@b25-ceo-2018-01018]\].

Studies have shown the relationship between obesity and inflammation. For example, systemic low grade chronic inflammation has been observed in obese patients \[[@b26-ceo-2018-01018]\]. Because inflammation and immune mechanisms play important roles in the development of Bell's palsy, our results suggest that obesity-associated low grade chronic inflammation may worsen the degree of paralysis in obese patients with Bell's palsy. In addition, obesity has been associated with other chronic diseases, suggesting that the degree of paralysis may be worsened by these comorbid diseases.

This study also found that WBC counts were significantly higher in the severe than in the mild to moderate palsy group. WBC counts are significantly higher in patients with Bell's palsy than in normal individuals, suggesting that inflammation is involved in the development of Bell's palsy \[[@b27-ceo-2018-01018]\].

We performed multivariate binary logistic regression analysis, using BMI, hypertension (HTN), diabetes mellitus (DM), and NLR as independent variables and recovery time as the dependent variable. The variance inflation factors of these independent variables were low (1.035, 1.169, 1.138, and 1.009, respectively) and did not show multicollinearity. Their regression coefficients were 1.515, --17.597, 32.420, and 2.510, respectively, but only DM was statistically significant (*P*=0.031). BMI (*P*=0.196) and HTN (*P*=0.162) were not statistically significant, whereas NLR tended toward significance (*P*=0.057). These results suggested that these factors may be statistically significant in studies on larger numbers of patients. Although the results of our multivariate analysis suggested that DM-associated deterioration in blood circulation may have an adverse effect on the prognosis of patients with facial palsy, recent studies on diabetes and recovery time from facial paralysis have reported that diabetes does not affect the prognosis of patients with Bell's palsy \[[@b28-ceo-2018-01018]\]. Thus, it remains unclear whether DM affects the prognosis of patients with Bell's palsy.

This study had several limitations. First, the time from the onset of paralysis to blood sampling was not constant. Second, because the relationships of neutrophils and lymphocytes with axon regeneration have not yet been clarified, the results of this study cannot explain the pathophysiology of Bell's palsy. Third, it is difficult to determine the exact recovery time by assessments at regular outpatient visits. Fourth, the number of subjects was relatively small, preventing sub-analyses. Fifth, we could not compare NLRs before and after treatment and before and after recovery. Sixth, we did not measure inflammatory markers (e.g., erythrocyte sedimentation rate or C-reactive protein concentration) other than WBC count due to the retrospective design of this study. The time to recovery from facial palsy was significantly longer in patients with high NLR than low NLR. NLR may therefore be a useful marker for predicting recovery time in patients with Bell's palsy.

HIGHLIGHTS
==========

▪ Higher neutrophil to lymphocyte ratio in patients with Bell's palsy was associated with longer recovery time.

▪ The neutrophil to lymphocyte ratio may be prognostic of recovery time in patients with Bell's palsy.
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![Relationships between hypertension (HTN), diabetes mellitus (DM), body mass index (BMI), and neutrophil to lymphocyte ratio (NLR) and recovery time in patients with Bell's palsy. Normal weight, BMI \<25 kg/m^2^ ; obesity, BMI ≥25 kg/m^2^ and normal NLR, ≤3.53; high NLR, \>3.53. \**P*\<0.05.](ceo-2018-01018f1){#f1-ceo-2018-01018}
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###### 

Baseline demographics and clinical characteristics of patients with Bell's palsy^[a)](#tfn1-ceo-2018-01018){ref-type="table-fn"}^

  Variable                                                               Value
  ---------------------------------------------------------------------- --------------------
  No. of patients                                                        51
   Male:female                                                           16:35
  Age (yr)                                                               39.7±20.1
  Recovery time (day)^[b)](#tfn2-ceo-2018-01018){ref-type="table-fn"}^   48.9±35.9
  Initial severity (H-B grade)                                           3.8±0.9
  BMI (kg/m^2^)                                                          23.2±4.2
  Underlying disease                                                     
   Obesity:non-obesity                                                   16:35
   HTN:non-HTN                                                           11:40
   DM:non-DM                                                             7:44
  Blood laboratory test                                                  
   Neutrophil (%)                                                        65.9±14.4
   Lymphocyte (%)                                                        26.1±11.1
   Monocyte (%)                                                          4.5±2.0
   Eosinophil (%)                                                        1.7±1.7
   Basophil (%)                                                          0.4±0.3
   NLR                                                                   3.8±3.7
   PLR                                                                   171.3±116.9
   Platelet count (/mL)                                                  284,588.2±91,036.5
   WBC count (/mL)                                                       8,501.6±3,016.1
   HbA1c (%)                                                             5.7±0.7
  Electrodiagnostic test                                                 
   ENoG 5 days after onset (%)                                           50.8±21.9

Values are presented as mean±standard deviation.

H-B grade, House-Brackmann grade; BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; NLR, neutrophil lymphocyte ratio (absolute neutrophil count/absolute lymphocyte count); PLR, platelet to lymphocyte ratio (platelet count/absolute lymphocyte count); WBC, white blood cell; HbA1c, glycated hemoglobin; ENoG, electroneuronography.

Mild palsy, H-B grade 2; moderate palsy, H-B grade 3, 4; severe palsy, H-B grade 5, 6.

Recovery time: time from the first day of facial palsy until the day it improved to H-B grade 1 or 2.

###### 

Baseline demographics and clinical characteristics of patients with mild to moderate and severe Bell's palsy^[a)](#tfn3-ceo-2018-01018){ref-type="table-fn"}^

  Variable                                                               Mild to moderate palsy   Severe palsy          *P*-value
  ---------------------------------------------------------------------- ------------------------ --------------------- --------------------------------------------------------
  No. of patients                                                        39                       12                    
  Male:female                                                            10:29                    6:6                   0.157
  Age (yr)                                                               38.6±19.5                43.3±22.2             0.571
  Recovery time (day)^[b)](#tfn4-ceo-2018-01018){ref-type="table-fn"}^   39.1±28.9                78.6±41.3             0.002^[\*](#tfn5-ceo-2018-01018){ref-type="table-fn"}^
  BMI (kg/m^2^)                                                          22.6±3.4                 25.1±5.9              0.069
  Underlying disease                                                                                                    
   Obesity:non-obesity                                                   9:30                     7:5                   0.033^[\*](#tfn5-ceo-2018-01018){ref-type="table-fn"}^
   HTN:non-HTN                                                           9:30                     2:10                  1.000
   DM:non-DM                                                             4:35                     3:9                   0.334
  Blood laboratory test                                                                                                 
   Neutrophil (%)                                                        63.8±14.4                72.9±12.4             0.053
   Lymphocyte (%)                                                        27.8±11.1                20.5±9.6              0.048^[\*](#tfn5-ceo-2018-01018){ref-type="table-fn"}^
   Monocyte (%)                                                          4.6±2.1                  4.1±1.9               0.506
   Eosinophil (%)                                                        1.9±1.8                  1.0±0.9               0.098
   Basophil (%)                                                          0.5±0.3                  0.3±0.2               0.112
   NLR                                                                   3.5±3.8                  4.8±3.2               0.048^[\*](#tfn5-ceo-2018-01018){ref-type="table-fn"}^
   PLR                                                                   143.2±100.4              195.9±160.0           0.807
   Platelet count (/mL)                                                  278,410.3±73,129.6       304,666.7±136,460.0   0.973
   WBC count (/mL)                                                       7,912.6±2,627.5          10,415.8±3,503.4      0.021^[\*](#tfn5-ceo-2018-01018){ref-type="table-fn"}^
   HbA1c (%)                                                             5.7±0.7                  5.9±0.7               0.154
  Electrodiagnostic test                                                                                                
   ENoG (%)                                                              56.1±18.8                33.6±23.3             0.010^[\*](#tfn5-ceo-2018-01018){ref-type="table-fn"}^

Values are presented as mean±standard deviation.

BMI, body mass index; HTN, hypertension; DM, diabetes mellitus; NLR, neutrophil to lymphocyte ratio (absolute neutrophil count/absolute lymphocyte count); PLR, platelet to lymphocyte ratio (platelet count/absolute lymphocyte count); WBC, white blood cell; HbA1c, glycated hemoglobin; ENoG, electroneuronography; H-B grade, House-Brackmann grade.

Mild palsy, H-B grade 2; moderate palsy, H-B grade 3, 4; severe palsy, H-B grade 5, 6.

Recovery time: time from the first day of facial palsy until the day it improved to H-B grade 1 or 2.

*P*\<0.05.23.2
